Ernexa Therapeutics Inc. is advancing its lead program, ERNA-101, toward an IND submission in the third quarter of this year and the initiation of a first-in-human trial in the fourth quarter for the treatment of platinum-resistant ovarian cancer.
T-cell engager company Kali Therapeutics Inc. licensed its lead product, CD19/BCMA/CD3 trispecific antibody KT-501, to Sanofi SA in a global deal that could be worth more than $1.2 billion. The San Mateo, Calif.-based biotech first emerged in 2024 and moved KT-501 into a phase Ia trial last week to treat adults with rheumatoid arthritis.
In the inflamed joints of rheumatoid arthritis, CD4+ T lymphocytes accumulate lipid droplets that make them vulnerable and promote their death, thereby amplifying joint inflammation. A study led by scientists at Mayo Clinic and Stanford University suggests that blocking the formation of these lipid droplets or their contents could offer a therapeutic strategy for this condition.
Third Arc Bio Inc. has closed a $52 million series A extension to advance its pipeline of multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications.
Alebund Pharmaceuticals (Hong Kong) Ltd. has described complement factor B (CFB) inhibitors reported to be useful for the treatment of glomerular disorders and rheumatoid arthritis.
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences and Xi’an Jiao Tong University Health Science Center found that Mesothelin (MSLN) was significantly elevated in rheumatoid arthritis (RA) patients and collagen-induced arthritis (CIA) rats and mice, where it drove osteoclast differentiation.
Kali Therapeutics Inc. has developed a novel T-cell engager (TCE) bispecific antibody, KT-502, targeting CD19 and CD3 for the treatment of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis.
Interleukin 1 receptor accessory protein (IL1RAP) is a receptor that activates signaling pathways triggered by IL1α/β, IL33 and IL36α/β/γ, which are involved in several autoimmune or inflammatory disorders, including psoriasis, gout or systemic sclerosis. Innovent Biologics Co. Ltd. presented data for their anti-IL1RAP antibody IBI-3011, a fully humanized IgG1 antibody targeting IL1RAP that blocks those pathways.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus and rheumatoid arthritis.
